Sage Journals: Discover world-class research

Abstract

Keywords

SGLT2 inhibitors diabetic nephropathy diabetic retinopathy

Get full access to this article

View all access options for this article.

References

Chen

Zhang

You

, et al. Investigating the impact of empagliflozin on the retina of diabetic mice. Eur J Ophthalmol 2025; 35: 252–261. doi:https://doi.org/10.1177/11206721241247585

Tesfaye

Paik

Roh

, et al. Empagliflozin and the risk of retinopathy in patients with type 2 diabetes. JAMA Ophthalmol 2025; 143: 62–71. doi:https://doi.org/10.1001/jamaophthalmol.2024.5219

Jacob

Varughese

. Optimising renal risk parameters in type 2 diabetes mellitus: perspectives from a retinal viewpoint. Clin Med (Lond) 2024; 24: 100031. doi:https://doi.org/10.1016/j.clinme.2024.100031

Shaw

Jenkins

. Diabetic retinopathy-another possible target for SGLT2 inhibitors? JAMA Ophthalmol 2025; 143: 71–72. doi:https://doi.org/10.1001/jamaophthalmol.2024.5364

Varughese

Varadhan

. SGLT2 Inhibitors and diabetic retinopathy: insights from the management of nephropathy. Eye (Lond) 2025; 39: 213–214. doi:https://doi.org/10.1038/s41433-024-03472-9

Translating the renoprotective effects of SGLT2 inhibitors to the diabetic retina

Abstract

Keywords

Get full access to this article

References